Clinical trials: Cognitive Deficit
Dementia, Cognitive Impairment
Functionally-tailored Oral Care Intervention for Community-dwelling Older Adults With Dementia and Their Caregivers
The specific aims of this study are: Aim 1. Develop a staged and modifiable dyadic oral care intervention to provide functionally-tailored oral care rehabilitation for community-dwelling persons with dementia (PWD) and need-based…
- Trial name
- NCT04238520
- Testing
- Functionally Tailored Oral Care Intervention, Control Intervention
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Xi Chen
Huntington's Disease
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in…
- Trial name
- PRECISION-HD2 (NCT03225846)
- Testing
- WVE-120102
- Where
- 26 sites in United States, Australia and 6 more
- Volunteers
- 88 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington Disease
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
- Trial name
- ADORE-DH (NCT03252535)
- Testing
- Cellavita HD lower dose, Cellavita HD higher dose
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- Azidus Brasil
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Sepsis, Delirium
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in…
- Conditions
- Sepsis, Delirium, Impaired Cognition
- Trial name
- MENDS2 (NCT01739933)
- Testing
- Dexmedetomidine, Propofol
- Where
- 11 sites in United States
- Volunteers
- 438 people
- Sponsor
- Vanderbilt University Medical Center
Heart Failure, Cognition Disorders
Cognitive Problems in Veterans With Heart Failure
We assessed the prevalence of cognitive/memory problems in veteran patients with heart failure, and evaluated its relationship to medication compliance.
- Trial name
- NCT01049308
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- US Department of Veterans Affairs
Hunter Syndrome
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
Study HGT-HIT-094 is a multicenter study designed to determine the effect on clinical parameters of neurodevelopmental status of monthly IT administration of idursulfase-IT 10 mg for 12 months in pediatric patients with Hunter…
- Trial name
- AIM-IT (NCT02055118)
- Testing
- idursulfase-IT, No IT treatment
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Shire
Alcohol Use Disorder, PTSD
Cognitive Remediation for Alcohol Use Disorder and Posttraumatic Stress Disorder
The project will examine whether a computerized neuroscience-based cognitive training program can improve cognitive functioning and recovery outcomes among Veterans with Alcohol Use Disorder and co-occurring PTSD.
- Conditions
- Alcohol Use Disorder, PTSD, Cognitive Dysfunction
- Trial name
- NCT02929979
- Testing
- Cognitive Training
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Mild Cognitive Impairment
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure.
- Trial name
- LATTICE (NCT03185208)
- Testing
- Lithium Carbonate
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Ariel Gildengers, MD
Parkinson's Disease
Cognitive Rehabilitation in Parkinson's Disease
We are testing a computer game-style rehabilitation program for people with Parkinson's disease (PD). People with PD often have difficulty with motor planning, such as initiating or starting movements.
- Trial name
- NCT01085968
- Testing
- PC based training
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Posttraumatic Stress Disorder, Depression
A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot
The goal of this pilot study is to develop and implement a larger scale, multi-site stepped collaborative care trial that targets injured patients with presentations of posttraumatic stress disorder (PTSD) and related…
- Conditions
- Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation
- Trial name
- TSOS6 (NCT02335125)
- Testing
- Motivational Interviewing, Cognitive Behavioral Therapy Elements, Psychotropic Drugs
- Volunteers
- 40 people
- Sponsor
- University of Washington
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
STIM+: PET Biomarker Education & Disclosure
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging.
- Trial name
- STIM+ (NCT04818255)
- Testing
- PET Biomarker Disclosure
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Michigan
Sedentary Lifestyle, Dementia, Mild
Smartphone App to Improve Physical Activity in Older Adults With MCI/Mild Dementia
The purpose of this study is to develop and test a physical activity-tracking smartphone app designed to facilitate physical activity in older adults with mild cognitive impairments or mild dementia.
- Conditions
- Sedentary Lifestyle, Dementia, Mild, Mild Cognitive Impairment, Memory and Thinking Problems
- Trial name
- NCT04950998
- Testing
- Moving Up - A
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Southern California
Mild Cognitive Impairment
Plasticity Using Stimulation and Habit: A Pilot Open-label rTMS Study for MCI
The goal of this pilot study is to determine whether a high-dose form of non-invasive brain stimulation is a promising and safe treatment for Mild Cognitive Impairment (MCI).
- Trial name
- PUSH-Pilot (NCT04503096)
- Testing
- High-dose accelerated rTMS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical University of South Carolina
Huntington Disease
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia.
- Trial name
- Reach2HD (NCT01590888)
- Testing
- PBT2
- Where
- 19 sites in United States, Australia
- Volunteers
- 109 people
- Sponsor
- Prana Biotechnology Limited
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Schizophrenia
Different Safety Profile of Risperidone and Paliperidone Extended-release
The main objective of this study was to assess subjective experiences related to secondary negative symptoms and cognitive performance in healthy volunteers in response to multiple doses of paliperidone ER and risperidone in a…
- Trial name
- NCT01284959
- Testing
- risperidone, paliperidone ER
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Sturge-Weber Syndrome
Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
The purpose of this research study is to gain a preliminary understanding of the safety of sirolimus in Sturge-Weber syndrome (SWS) and determine best outcomes to be used to assess the utility of sirolimus for the treatment of…
- Trial name
- NCT03047980
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Anne Comi, MD
Mild Cognitive Impairment, Mild Neurocognitive Disorder
Noninvasive Brain Stimulation for Mild Cognitive Impairment
The goal of this study is to test the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) as a treatment for Mild Cognitive Impairment (MCI).
- Conditions
- Mild Cognitive Impairment, Mild Neurocognitive Disorder, Cognitive Decline, Mental Deterioration
- Trial name
- NCT03331796
- Testing
- Active rTMS (Bilateral DLPFC), Active rTMS (Bilateral LPC)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Palo Alto Veterans Institute for Research
Cognitive Impairment, Emergency Care
Pathway to Detection & Differentiation of Delirium & Dementia in the Emergency Department
This is an observational study of the pragmatic implementation of an ED screening, outpatient referral, and care coordination process for older ED patients who may have UCID.
- Conditions
- Cognitive Impairment, Emergency Care, Dementia, Delirium
- Trial name
- IMPACT (NCT04846322)
- Testing
- PD4ED 3-step intervention (ED assessment, outpatient assessment, Brain health plan)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Yale University